A Single-Center Analysis of Methylprednisolone Use during Pediatric Cardiopulmonary Bypass

Molly Dreher1, Andrew C Glatz1, Andrea Kennedy1

  • 1The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Insights

Eliminating methylprednisolone from cardiopulmonary bypass (CPB) prime did not improve outcomes in pediatric cardiac surgery patients. Steroid use was linked to increased wound infections and respiratory failure, prompting its continued exclusion from CPB prime.

Area of Science:

  • Pediatric Cardiac Surgery
  • Cardiopulmonary Bypass (CPB)
  • Inflammatory Response

Background:

  • Cardiopulmonary bypass (CPB) can trigger an inflammatory response, potentially more severe in pediatric patients.
  • Corticosteroids are sometimes used in CPB prime to mitigate this response, but their effectiveness and risks are debated.
  • Methylprednisolone use in CPB prime was evaluated due to recent controversies.

Purpose of the Study:

  • To assess the clinical effectiveness and safety of methylprednisolone in the CPB prime for pediatric cardiac surgery.
  • To determine if eliminating methylprednisolone from CPB prime impacts patient outcomes.

Main Methods:

  • A quality improvement project was conducted at The Children's Hospital of Philadelphia.
  • Methylprednisolone was removed from the CPB prime for a 6-month period.
  • Clinical outcomes of 222 patients (post-elimination) were compared to 303 patients (pre-elimination) using The Society of Thoracic Surgeons Congenital Heart Surgery Database.

Main Results:

  • No significant clinical benefit was observed in patients who received methylprednisolone in the CPB prime.
  • Patients receiving methylprednisolone showed a significantly higher incidence of postoperative wound infection (p = .037) and respiratory failure requiring tracheostomy (p = .035).
  • No significant differences in outcomes were found in neonates, regardless of steroid exposure.

Conclusions:

  • Methylprednisolone in CPB prime offers no discernible clinical benefit for pediatric cardiac surgery patients.
  • The use of methylprednisolone in CPB prime may increase the risk of wound infections and respiratory complications.
  • The institution continues to exclude methylprednisolone from CPB prime, while still allowing its intraoperative use as indicated.

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.3K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
426
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
319
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
634
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
719